Johnson & Johnson $JNJ Shares Purchased by Motco

Motco lifted its position in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,301 shares of the company’s stock after purchasing an additional 337 shares during the period. Johnson & Johnson comprises about 1.1% of Motco’s portfolio, making the stock its 28th biggest holding. Motco’s holdings in Johnson & Johnson were worth $11,911,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Clark Asset Management LLC lifted its stake in shares of Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after purchasing an additional 3,025 shares during the period. Apexium Financial LP raised its position in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after acquiring an additional 2,310 shares during the period. Avanza Fonder AB raised its position in Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares during the period. Joel Isaacson & Co. LLC raised its position in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after acquiring an additional 2,526 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after acquiring an additional 4,816 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Royal Bank Of Canada restated an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Finally, UBS Group upped their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $186.94 on Wednesday. The firm has a 50-day simple moving average of $182.72 and a 200-day simple moving average of $166.92. The stock has a market capitalization of $450.40 billion, a price-to-earnings ratio of 18.04, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.